STLNNasdaqServices-Offices & Clinics of Doctors of MedicineFiscal year ends December 31Also trades as DFPH, STLNW
Starling Oncology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$6.46+0.03 (+0.47%)
Close on Oct 19, 2026
- Market cap
- $665.58M
- P/E (TTM)
- –
- Dividend yield
- –
Starling Oncology, Inc. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| Specialty pharmacy | $269.18M | $179.92M | – | – | – | – | 53.5% | +49.6% |
| Patient services | $228.99M | $204.88M | $213.50M | $166.79M | $124.07M | $116.82M | 45.5% | +11.8% |
| Clinical trials & other | $4.56M | $8.61M | $6.90M | $6.36M | $6.38M | $6.81M | 0.9% | -47.0% |
| Dispensary | – | $3.00M | $103.84M | $79.34M | $72.55M | $63.89M | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| Specialty Pharmacy | $269.18M | $179.92M | – | – | – | – | 53.5% | +49.6% |
| Patient services | $228.99M | $204.88M | $213.50M | $166.79M | $124.07M | $116.82M | 45.5% | +11.8% |
| FFS revenue | $148.51M | $136.20M | $143.13M | $105.44M | $69.79M | $79.44M | 29.5% | +9.0% |
| Capitated revenue | $80.48M | $68.69M | $70.37M | $61.34M | $54.29M | $37.38M | 16.0% | +17.2% |
| Clinical trials & other | $4.56M | $8.61M | $6.90M | $6.36M | $6.38M | $6.81M | 0.9% | -47.0% |
| Dispensary | – | $179.92M | $103.84M | $79.34M | $72.55M | $63.89M | – | – |
By region
From the segment and revenue-disaggregation notes of Starling Oncology's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.